… by the activation of M 1 and M 3 receptors while inhibitory M 2 receptors limit ACh release
by negative feedback mechanisms to the M 1 and M 3 receptors. M 2 receptors, abundant on …

Absorption, distribution, metabolism and excretion of desloratadine, fexofenadine, levocetirizine,
and mizolastine in humans have been compared. The time required to reach peak …

Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML),
inducing durable responses and prolonged progression-free survival. However, plasma …

Purpose There is a considerable variability in the level of molecular responses achieved with
imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could …

Using high-performance liquid chromatography–tandem mass spectrometry, we assessed
trough imatinib plasma levels in 68 patients with chronic myeloid leukemia (CML) who …

The correct use of inhalation devices is an inclusion criterion for all studies comparing inhaled
treatments. In real life, however, patients may make many errors with their usual inhalation …

We studied the relation between adherence to imatinib measured with microelectronic
monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) and …

Despite the excellent efficacy of imatinib in chronic myeloid leukemia (CML), the response
in patients is heterogeneous, which may in part be caused by pharmacogenetic variability. …

The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch
a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in …

… Humbert and M. Molimard contributed to the study concept, design, analysis and … Conflict
of interest: M. Humbert has relationships with drug companies including AstraZeneca, GSK, …